Wilden's air-operated, double-diaphragm pumps feature bolted product containment, self-priming and dry-run capabilities, and are direct replacements for existing clamped and bolted pumps from the company.
Wilden, part of PSG, a Dover company, added PS220/230 FIT 25 mm, one-inch metal air-operated, double-diaphragm pumps to its lineup. The pumps feature bolted product containment and are direct replacements for existing clamped and bolted pumps from the company. Direct replacement allows for the pumps to fit bolt-to-bolt and pipe-to-pipe in existing fluid-handling piping systems. The pumps are shear sensitive and feature self-priming and dry-run capabilities, and offer the longest mean time between repair (MTBR), and increased anti-freezing and on/off reliability.
These pumps are equipped with the company’s Pro-Flo Shift Air Distribution System (ADS) for energy efficiency, which incorporates an air control spool that automatically restricts the amount of air going into the pump during the latter part of each stroke, eliminating over-filling of the air chamber and resulting in reduced energy consumption, according to the company. The pumps, available in aluminum, stainless steel, and ductile iron, are available with maximum discharge pressures to 8.6 bar (125 psig), maximum flow rates to 254 lpm (56 gpm), and maximum suction lifts to 6.9 m (22.7 ft.) dry, 9.0 m (29.5 ft) wet. Diaphragms are available in Buna-N, EPDM, Polyurethane, PTFE, Saniflex, Viton, and Wil-Flex.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications
December 10th 2024This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.